Lipocine (NASDAQ:LPCN) Stock Price Passes Below 200-Day Moving Average – Time to Sell?

Lipocine Inc. (NASDAQ:LPCN)’s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $4.07 and traded as low as $3.50. Lipocine shares last traded at $3.99, with a volume of 470,538 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Lipocine in a research report on Saturday. They issued a “hold” rating on the stock.

Lipocine Stock Performance

The stock has a market cap of $21.35 million, a P/E ratio of -5.25 and a beta of 1.52. The stock’s fifty day moving average is $3.24 and its 200 day moving average is $4.06.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.35 million.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC grew its position in Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the period. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 as of its most recent SEC filing. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.